Stock Watch: Donanemab Provides Cover For Lilly’s Second-Quarter Insulin Challenge
An Accelerated Approval Tomorrow Trumps Biosimilar Competition Today
Lilly’s second-quarter earnings announcement relegated its core business in favor of its experimental Alzheimer’s disease drug. This diverted attention away from competitive reimbursement challenges that may be affecting its insulin business.
You may also be interested in...
Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.
Viatris has revealed its commercial strategy for its Semglee insulin glargine biosimilar in the US after winning a landmark first designation of interchangeability for the product from the FDA that will allow pharmacy-level substitution with a year of exclusivity.